{"id":"NCT03602560","sponsor":"Gilead Sciences","briefTitle":"ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","officialTitle":"A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-01","primaryCompletion":"2020-02-16","completion":"2020-02-16","firstPosted":"2018-07-27","resultsPosted":"2022-05-31","lastUpdate":"2022-08-02"},"enrollment":265,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Biliary Cholangitis"],"interventions":[{"type":"DRUG","name":"seladelpar 5-10 mg","otherNames":[]},{"type":"DRUG","name":"seladelpar 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Seladelpar 5-10 mg","type":"EXPERIMENTAL"},{"label":"Seladelpar 10 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)\n\nThe participants might enter the ongoing open-label safety study (NCT03301506) following this double-blind study.","primaryOutcome":{"measure":"Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3","timeFrame":"Month 3","effectByArm":[{"arm":"Seladelpar 5-10 mg","deltaMin":32,"sd":null},{"arm":"Seladelpar 10 mg","deltaMin":43,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":156,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","France","Germany","Greece","Hungary","Israel","Italy","Mexico","Netherlands","New Zealand","Poland","Romania","Russia","Serbia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":89},"commonTop":["Pruritus","Abdominal pain upper","Nausea","Fatigue","Arthralgia"]}}